Literature DB >> 11896702

Reduction of [VO2(ma)2]- and [VO2(ema)2]- by ascorbic acid and glutathione: kinetic studies of pro-drugs for the enhancement of insulin action.

Bin Song1, Nicolas Aebischer, Chris Orvig.   

Abstract

To shed light on the role of V(V) complexes as pro-drugs for their V(IV) analogues, the kinetics of the reduction reactions of [VO2(ma)2]- or [VO2(ema)2]- (Hma = maltol, Hema = ethylmaltol), with ascorbic acid or glutathione, have been studied in aqueous solution by spectrophotometric and magnetic resonance methods. EPR and 51V NMR studies suggested that the vanadium(V) in each complex was reduced to vanadium(IV) during the reactions. All the reactions studied showed first-order kinetics when the concentration of ascorbic acid or glutathione was in large excess and the observed first-order rate constants have a linear relationship with the concentrations of reductant (ascorbic acid or glutathione). Potentiometric results revealed that the most important species in the neutral pH range is [VO2(L)2]- for the V(V) system where L is either ma- or ema-. An acid dependence mechanism was proposed from kinetic studies with varying pH and varying maltol concentration. The good fits of the second order rate constant versus pH or the total concentration of maltol, and the good agreement of the constants obtained between fittings, strongly supported the mechanism. Under the same conditions, the reaction rate of [VO2(ma)2]- with glutathione is about 2000 times slower than that of [VO2(ma)2]- with ascorbic acid, but an acid dependence mechanism can also be used to explain the results for the reduction with glutathione. Replacing the methyl group in maltol with an ethyl group has little influence on the reduction rate with ascorbic acid, and the kinetics are the same no matter whether [VO2(ma)2]- or [VO2(ema)2]- is reduced.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896702     DOI: 10.1021/ic0111684

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  5 in total

1.  Biotransformations of Antidiabetic Vanadium Prodrugs in Mammalian Cells and Cell Culture Media: A XANES Spectroscopic Study.

Authors:  Aviva Levina; Andrew I McLeod; Anna Pulte; Jade B Aitken; Peter A Lay
Journal:  Inorg Chem       Date:  2015-04-23       Impact factor: 5.165

2.  Colorimetric detection of hydrogen peroxide by dioxido-vanadium(V) complex containing hydrazone ligand: synthesis and crystal structure.

Authors:  Sunshine D Kurbah; Ibanphylla Syiemlieh; Ram A Lal
Journal:  R Soc Open Sci       Date:  2018-03-14       Impact factor: 2.963

Review 3.  Why Antidiabetic Vanadium Complexes are Not in the Pipeline of "Big Pharma" Drug Research? A Critical Review.

Authors:  Thomas Scior; Jose Antonio Guevara-Garcia; Quoc-Tuan Do; Philippe Bernard; Stefan Laufer
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 4.  Vanadium in Biological Action: Chemical, Pharmacological Aspects, and Metabolic Implications in Diabetes Mellitus.

Authors:  Samuel Treviño; Alfonso Díaz; Eduardo Sánchez-Lara; Brenda L Sanchez-Gaytan; Jose Manuel Perez-Aguilar; Enrique González-Vergara
Journal:  Biol Trace Elem Res       Date:  2018-10-22       Impact factor: 3.738

5.  The liposomal delivery of hydrophobic oxidovanadium complexes imparts highly effective cytotoxicity and differentiating capacity in neuroblastoma tumour cells.

Authors:  Elsa Irving; Aristides D Tagalakis; Ruhina Maeshima; Stephen L Hart; Simon Eaton; Ari Lehtonen; Andrew W Stoker
Journal:  Sci Rep       Date:  2020-10-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.